Amarin Corp Plcuk (AMRN) Income from Continuing Operations (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Income from Continuing Operations of 7650000.0 for Q2 2026, up 45.89% year-over-year from 5243520.94 in Q2 2025, and up 27.23% quarter-over-quarter from 10512000.0 in Q1 2026.
Amarin Corp Plcuk (AMRN) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Income from Continuing Operations for 17 consecutive years, with 7650000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations rose 45.89% year-over-year to 7650000.0; the TTM figure through Jun 2026 stood at 15362000.0 (up 80.63% YoY), while the FY2025 annual figure was 27036000.0, up 53.31% from the prior year.
- Income from Continuing Operations advanced to 7650000.0 in Q2 2026 per AMRN's latest filing, from 10512000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 28806000.0 in Q4 2022 and bottomed at 69956000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 12289055.56 across 5 years, with a median of 12325500.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 1841.14% — and 2025, when it surged 143.3%.
- Amarin Corp Plc\Uk's Income from Continuing Operations stood at 28806000.0 in 2022, then slumped by 54.6% to 13079000.0 in 2023, then plunged by 286.06% to 24335000.0 in 2024, then soared by 143.3% to 10538000.0 in 2025, then plunged by 172.59% to 7650000.0 in 2026.
- Business Quant data shows AMRN's Income from Continuing Operations at 7650000.0 in Q2 2026, 10512000.0 in Q1 2026, and 10538000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | -7.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.65 Mn |
| Mar 31, 2026 | -10.51 Mn |
| Dec 31, 2025 | 10.54 Mn |
| Sep 30, 2025 | -7.74 Mn |
| Jun 30, 2025 | -14.14 Mn |
| Mar 31, 2025 | -15.70 Mn |
| Dec 31, 2024 | -24.34 Mn |
| Sep 30, 2024 | -25.13 Mn |
| Jun 30, 2024 | 1.52 Mn |
| Mar 31, 2024 | -9.95 Mn |
| Dec 31, 2023 | 13.08 Mn |
| Sep 30, 2023 | -19.31 Mn |
| Jun 30, 2023 | -17.56 Mn |
| Mar 31, 2023 | -16.46 Mn |
| Dec 31, 2022 | 28.81 Mn |
| Sep 30, 2022 | -5.14 Mn |
| Jun 30, 2022 | -69.96 Mn |
| Mar 31, 2022 | -31.56 Mn |
| Dec 31, 2021 | 26.63 Mn |
| Sep 30, 2021 | -13.15 Mn |